Biogen
Search results
Learn about Alnylam's pipeline of investigational RNAi therapeutics and how the company is leading the translation of RNAi into a new class of innovative medicines to treat a variety of conditions.
- Clinical Trials
Clinical Trials Transparency. We are committed to ensuring...
- Our Products
Find information about Alnylam's pharmaceutical products:...
- Investor Relations
The Investor Relations website contains information about...
- Events & Presentations
Alnylam Pharmaceuticals Conference Call to Discuss Results...
- Press Releases
Alnylam to Present Detailed Results from the HELIOS-B Phase...
- Alnylam Pharmaceuticals Press Release
Alnylam Highlights Significant Progress with Platform...
- Alnylam® Pharmaceuticals
OUR PIPELINE. Our robust pipeline of investigational RNAi...
- Clinical Trials
OUR PIPELINE. Our robust pipeline of investigational RNAi therapeutics is currently focused on diseases with high unmet medical need, including transthyretin amyloidosis, rare diseases, cardiovascular diseases, metabolic diseases, and neurological diseases.
Dec 15, 2022 · Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day. Dec 15, 2022. − Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs –. − Pipeline Programs and Scientific Innovation ...
Dec 15, 2020 · Alnylam’s commercial RNAi therapeutic products are ONPATTRO ® (patisiran), GIVLAARI ® (givosiran), and OXLUMO™ (lumasiran). Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.
Dec 13, 2023 · Alnylam showcases its RNAi therapeutics pipeline and platform innovation, including new delivery systems and targets for liver, CNS, adipose, and muscle diseases. The Company anticipates filing INDs for nine or more programs by 2025 and presents positive Phase 1 data for ALN-TTRsc04 and ALN-KHK.
Nov 19, 2021 · Alnylam is executing on its “Alnylam P 5 x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation ...
Clinical Trials Transparency. We are committed to ensuring our clinical trial information is accessible to patients, caregivers, health care providers, researchers, and the general public as a way to further scientific discovery and advance public health. LEARN MORE ›.
